Schonfeld Strategic Advisors LLC 89bio, Inc. Transaction History

Schonfeld Strategic Advisors LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$7.31 - $10.9 $683,967 - $1.02 Million	-93,566 Reduced 69.8%	40,488 $324,000
Q1 2024 May 15, 2024	BUY	$8.13 - $13.77 $457,686 - $775,195	56,296 Added 72.4%	134,054 $1.56 Million
Q4 2023 Feb 14, 2024	SELL	$6.66 - $16.03 $1.33 Million - $3.2 Million	-199,804 Reduced 71.99%	77,758 $868,000
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $631,887 - $814,404	41,958 Added 17.81%	277,562 $4.29 Million
Q2 2023 Aug 14, 2023	SELL	$14.15 - $22.03 $1.66 Million - $2.59 Million	-117,642 Reduced 33.3%	235,604 $4.46 Million
Q1 2023 May 15, 2023	SELL	$10.48 - $16.94 $1.33 Million - $2.15 Million	-126,797 Reduced 26.41%	353,246 $5.38 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $718,610 - $1.66 Million	130,183 Added 37.21%	480,043 $6.11 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $319,775 - $741,202	105,886 Added 43.4%	349,860 $2.03 Million
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $484,407 - $931,731	231,774 Added 1899.79%	243,974 $787,000
Q1 2022 May 16, 2022	BUY	$3.45 - $14.99 $42,090 - $182,878	12,200 New	12,200 $46,000
Q1 2021 May 17, 2021	SELL	$20.22 - $26.73 $920,010 - $1.22 Million	-45,500 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$23.16 - $28.08 $254,760 - $308,880	-11,000 Reduced 19.47%	45,500 $1.11 Million
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $1.38 Million - $2.19 Million	56,500 New	56,500 $1,000
Q1 2020 May 15, 2020	SELL	$16.4 - $41.77 $440,175 - $1.12 Million	-26,840 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$19.75 - $33.44 $530,090 - $897,529	26,840 New	26,840 $705,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $365M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.